Study of the Evolution of the Expression of the LAMP-2 Protein During the Advance in Age

Study of the Evolution of the Expression of the LAMP-2 Protein During the Advance as Well as Variations and Allelic Mutations in the Main Genes Involved in the Occurrence of Age-related Myelodysplastic Syndromes

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06357923

Enrollment

100

Registered

2024-04-10

Start date

2024-09-26

Completion date

2026-09-26

Last updated

2024-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging

Brief summary

Recruitment on the RAV pole in consultation or day hospital. Competitive recruitment of subjects \> 60 years of age respecting a male/female ratio = 1.

Detailed description

Recruitment on the RAV pole in consultation or day hospital. Competitive recruitment of subjects \> 60 years of age respecting a male/female ratio = 1. After explanations and collection consent, collection of the patient's socio-demographic and medical characteristics and then carrying out a Peripheral venous blood sample (2 x 5ml tubes).

Interventions

DIAGNOSTIC_TESTdosage

Presence of mutation on the gene panel and Frequency of allele variation

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

60 Years to 99 Years

Healthy volunteers

Inclusion criteria

* Men and women over 60 years of age.

Exclusion criteria

* Inability to Understand Consent, * Non-Security Beneficiaries * social, subjects protected by law, subjects deprived of liberty, * history of breast cancer, * brain tumor, * melanoma, * colon cancer, * lung cancer, * prostate cancer, * lymphoma, * myeloma, * syndrome myelodysplastic/myeloproliferative, * leukemia, * history of radiation therapy.

Design outcomes

Primary

Measure	Time frame	Description
Expression level of LAMP2 (protein and isoform A and B mRNA)	day 0	dosage

Secondary

Measure	Time frame	Description
Presence of mutation in the Oncomin Myeloid Reasearch Assay gene panel targeting approximately 40 Different genes	day 0	dosage

Countries

France

Contacts

Primary ContactAndrea CICCONE

ciccone.a@hu-nice.fr0492034702

Backup Contactmarion causeret

causeret.m@chu-nice.fr0492034702

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026